News and Trends 16 Jan 2018 Oxford Firm Recruits Two Partners to Build Drug Discovery AI e-Therapeutics has teamed up with AI experts Intellegens and Biorelate to improve its technology for computer-based drug discovery. Based in Oxford, e-Therapeutics has the mission of reducing the time and money it costs to develop new drugs with the help of artificial intelligence. Its platform can explore large amounts of public and private databases to […] January 16, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Dutch Biotech Joins International Effort to Eradicate Polio Batavia Biosciences joins an international consortium to develop and manufacture a safer type of polio vaccine. Their ultimate goal is to eradicate the disease. Based in Leiden, the Netherlands, Batavia Biosciences specializes in the development and production of viruses and proteins. Its expertise has attracted an international consortium to recruit Batavia in their effort to […] January 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Young Oxford Biotech Raises €22.5M to Develop a Universal Flu Vaccine Vaccitech has closed a Series A fundraising that will support clinical trials with its vaccine technology against influenza and prostate cancer. Spun out from Oxford University in 2016, Vaccitech has now closed its Series A fundraising round. Amounting to a total of £20M (€22.5M), the round was co-led by GV, Oxford Sciences Innovation and Sequoia China, and joined […] January 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jan 2018 Mars Astronauts Might Wear Spacesuits Made of Fungi A team of biodesigners is getting us ready to live on Mars by creating the clothes that future Martians will use using fungi to create the materials. Science fiction has been preparing us for the colonization of Mars for over a century. Many see the planet as an alternative home for when we destroy or overcrowd […] January 13, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jan 2018 French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa GenSight will start a clinical trial in the UK testing a combination of gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa. The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a first clinical trial in the UK testing a new type of therapy with the […] January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 10 Jan 2018 Infographic: All You Need to Know About Checkpoint Inhibitors Everything you need to know about what checkpoint inhibitors are and why they have caused a wave of hype for cancer immunotherapies. Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, […] January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 Jan 2018 Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […] January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 6 Jan 2018 A Self-Portrait of the Microbes that Live on our Skin Is a portrait fully complete without portraying the millions of bacteria that live on our skin? Mellissa Fisher makes them the focus of her self-portraits. British artist Mellissa Fisher creates quite unique portraits. The material for her face sculptures is agar rich in nutrients, the same one that scientists use to grow bacteria and fungi […] January 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2018 Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech Takeda has offered to acquire TiGenix subject to the upcoming European approval of its lead stem cell therapy for Crohn’s disease, Cx601. Short of two years after partnering with TiGenix for the development of a stem cell therapy, Takeda has offered to buy the remaining shares of the company in Euronext Brussels and the Nasdaq […] January 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 German Biotech Raises Record $270M Series A for Individualized Cancer Therapies BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and mRNA technologies. BioNTech is kicking off the new year with great news. The company has closed its Series A with $270M (€225M) — a record amount in Germany for such an early funding round. The fundraising was led by the […] January 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email